AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,155,720 | +358.4% | 42,620 | +323.1% | 0.05% | +350.0% |
| Q2 2023 | $470,308 | -62.4% | 10,073 | -55.9% | 0.01% | -65.7% |
| Q4 2022 | $1,251,084 | -10.8% | 22,830 | -44.5% | 0.04% | -28.6% |
| Q3 2022 | $1,402,000 | +749.7% | 41,167 | +135.1% | 0.05% | +600.0% |
| Q2 2022 | $165,000 | -2.4% | 17,509 | +46.9% | 0.01% | -12.5% |
| Q1 2022 | $169,000 | -30.2% | 11,916 | +42.8% | 0.01% | -63.6% |
| Q1 2021 | $242,000 | +11.0% | 8,343 | -1.3% | 0.02% | -4.3% |
| Q4 2020 | $218,000 | +7.9% | 8,452 | +28.7% | 0.02% | +76.9% |
| Q3 2020 | $202,000 | – | 6,568 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |